Article
Medicine, General & Internal
Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, Elena Elez, Takayuki Yoshino, Alberto Sobrero, James Yao, Pilar Garcia-Alfonso, Judit Kocsis, Antonio Cubillo Gracian, Andrea Sartore-Bianchi, Taroh Satoh, Violaine Randrian, Jiri Tomasek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csoszi, Chiara Cremolini, Francois Ghiringhelli, Ardaman Shergill, Howard S. Hochster, John Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng
Summary: This study evaluated the efficacy and safety of fruquintinib, a highly selective and potent oral inhibitor of VEGFRs 1, 2, and 3, in patients with advanced, chemotherapy-refractory colorectal cancer. The results showed that fruquintinib significantly prolonged overall survival compared to placebo in patients with refractory metastatic colorectal cancer, with clinical significance. Therefore, fruquintinib could become a global treatment option for patients with refractory metastatic colorectal cancer.
Review
Biochemistry & Molecular Biology
Daniele Lavacchi, Giandomenico Roviello, Alessia Guidolin, Silvia Romano, Jacopo Venturini, Enrico Caliman, Agnese Vannini, Elisa Giommoni, Elisa Pellegrini, Marco Brugia, Serena Pillozzi, Lorenzo Antonuzzo
Summary: The management of patients with metastatic colorectal cancer (mCRC) involves a continuum of care, with trifluridine/tipiracil and regorafenib being the main treatment options. Fruquintinib, a VEGFR inhibitor, has shown anti-tumor activity in preclinical models and has been approved for chemo-refractory mCRC patients. The phase III FRESCO trial and FRESCO-2 trial demonstrated the efficacy of fruquintinib in heavily pretreated patients, with an advantage in overall survival. This review discusses the clinical development of fruquintinib and its potential impact on the continuum of care for colorectal cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Qi Zhang, Mifen Chen, Zhenghang Wang, Changsong Qi, Yanshuo Cao, Junyan Zhang, Zhi Peng, Xicheng Wang, Ming Lu, Lin Shen, Jian Li
Summary: This ambispective observational cohort study evaluated the differences in efficacy and safety between regorafenib and fruquintinib in patients with refractory metastatic colorectal cancer (mCRC) in China. The study found that regorafenib and fruquintinib had similar efficacy in a real-world setting and their toxicity profiles were also similar but with different frequencies. Additionally, the sequence of regorafenib followed by fruquintinib showed longer overall survival.
CLINICAL COLORECTAL CANCER
(2022)
Review
Oncology
Tomohiro Enokida, Makoto Tahara
Summary: Anti-VEGFR therapy is crucial in treating thyroid cancer but can lead to dangerous adverse reactions. To minimize risks, physicians need to understand the characteristics of these reactions and take appropriate measures. The development of multitarget tyrosine kinase inhibitors has improved prognosis, but effective management of related adverse events is essential.
Article
Oncology
Christopher Kwok, Adam Khorasanchi, Sarah P. Psutka, Megan Hinkley, Shawn Dason, Debasish Sundi, Yuanquan Yang, Yajing Yang, Claire Verschraegen, Evan E. Gross, Delaney Orcutt, Ming Yin
Summary: This study retrospectively evaluated the efficacy and toxicity of Lenvatinib and everolimus combination therapy in mRCC patients who had previously received ICI and TKI treatment. The results showed that LE therapy had modest efficacies following ICI/TKI treatment, and patients with favorable risk or treated earlier had better treatment response.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ying Jin, Jin Li, Lin Shen, Jianming Xu, Yanqiao Zhang, Jingdong Zhang, Hongming Pan, Xiujuan Qu, Yamin Chen, Qiang Zhang, Jinnan Li, Miaomiao Sun, Shukui Qin
Summary: This study compared the efficacy of fruquintinib with other TKIs in the treatment of third-line metastatic colorectal cancer (mCRC) patients. The results showed that fruquintinib significantly prolonged progression-free survival (PFS) compared to other TKIs, especially in patients with specific characteristics such as multiple metastasis sites and lung metastasis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Shuai Liu, Lu Lu, Feng Pan, Chunsheng Yang, Jing Liang, Jinfeng Liu, Jian Wang, Rong Shen, Fu-Ze Xin, Nan Zhang
Summary: This study retrospectively evaluated the efficacy and safety of oral fruquintinib in mCRC patients, showing consistent clinical activity with previous clinical trials and manageable side effects in real-world settings.
Article
Oncology
Yuming Wan, Deyun Luo
Summary: This case report describes a patient with metastatic colorectal cancer who received third-line treatment with fruquintinib, raltitrexed, and S-1. The combination therapy achieved a partial response and allowed for surgical resection, leading to an extended progression-free survival. The findings suggest that this regimen might be effective as a late-line therapy for metastatic colorectal cancer.
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2023)
Article
Oncology
Shukui Qin, Jin Li, Yuxian Bai, Yanhong Deng, Lei Yang, Rui-Hua Xu, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Jianming Xu, Cike Peng, Yun Chen, Hongyan Li, Ning Wang, Xiaojun Guo, Mengye Peng, Songhua Fan, Lin Shen
Summary: The study aimed to assess the benefits of fruquintinib as a third-line treatment for mCRC patients and found that it significantly improved patients' quality-adjusted survival time, regardless of prior targeted therapy.
Article
Oncology
Yefei Shu, Song Zheng
Summary: This case reports a female patient with mCRC who developed severe rashes after taking fruquintinib for 2 weeks. While fruquintinib has shown good safety and manageable toxicity in previous trials, rare cases of severe rash reactions may occur in some patients. This highlights the importance of monitoring for adverse reactions in patients receiving fruquintinib.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Daisuke Obinata, Daigo Funakoshi, Fuminori Sakurai, Tsuyoshi Yoshizawa, Junichi Mochida, Kenya Yamaguchi, Satoru Takahashi
Summary: This study aimed to investigate the efficacy of sequential nivolumab treatment for metastatic renal cancer. The results showed that the overall survival was significantly longer in the 2017-2020 group compared to the 2014-2016 group. Nivolumab treatment as second-line therapy and prompt switching to nivolumab were identified as important factors for improved survival. These findings suggest the importance of sequential nivolumab treatment in patients who have received first-line molecular targeted therapy.
Article
Oncology
Samuel A. Jacobs, James J. Lee, Thomas J. George, James L. Wade, Philip J. Stella, Ding Wang, Ashwin R. Sama, Fanny Piette, Katherine L. Pogue-Geile, Rim S. Kim, Patrick G. Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F. Kiesel, Jan H. Beumer, Norman Wolmark, Peter C. Lucas, Carmen J. Allegra, Ashok Srinivasan
Summary: This study aimed to determine the recommended phase II dose and efficacy of neratinib combined with cetuximab in patients with metastatic colorectal cancer, particularly those who were resistant to anti-EGFR therapy. The study found that the recommended dose of neratinib in this combination therapy was well tolerated with a low incidence of adverse events, and while there were no objective responses, stable disease was observed at all neratinib doses. Additionally, HER2 amplification was more frequently detected in tissue and blood samples post-anti-EGFR therapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Lin-Quan Tang, Xiao-Yun Li, Zhi-Ming Li, Zhi-Gang Liu, Miao-Zhen Lin, Huan Zhou, Qi-Wen Yu, Jian Zhou, Chong Zhao, Ze-Bin Chen, Xi-Cheng Wang, Jia-Yu Peng, Qiu-Yan Chen, Wen-Feng Fang, Yun-Peng Yang, Bei Zhang, Liang-Ping Xia, Pi-Li Hu, Wei-Han Hu, Yi-Jie Li, Hai-Qiang Mai, Xiu-Yu Cai
Summary: Apatinib combined with capecitabine shows promising efficacy as a second-line treatment option in pretreated platinum-refractory recurrent or metastatic nasopharyngeal carcinoma patients.
Article
Oncology
F. Janku, S. Bauer, K. Shoumariyeh, R. L. Jones, A. Spreafico, J. Jennings, C. Psoinos, J. Meade, R. Ruiz-Soto, P. Chi
Summary: This study demonstrates the efficacy and safety of Ripretinib in patients with KIT-altered metastatic melanoma. The drug shows promising results and may play a meaningful role in treating these patients.
Article
Oncology
Yan Song, Tao Qu, Honggang Zhang, Yongkun Sun, Chengxu Cui, Yihebali Chi, Wen Zhang, Xingyuan Wang, Lin Yang
Summary: This study aimed to evaluate the safety and effectiveness of fruquintinib in Chinese mCRC patients, with findings showing a relatively low incidence of TRAEs, and consistent PFS and OS results compared to randomized controlled trials. Patients with hypertension or hypothyroidism may experience a potential survival extension of approximately 6 months.
CANCER MANAGEMENT AND RESEARCH
(2021)